poisar

Stocks · News reference

Cellectis Presents Preclinical Data for .HEAL-101 at ESGCT 2026

Cellectis announced positive preclinical data for its in vivo gene-editing candidate .HEAL-101, which targets APOC3 for the treatment of severe hypertriglyceridemia.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CLLS
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Glancy Prongay Wolke & Rotter Llp

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

    Cellectis S.A. announced on September 14, 2026, that it would discontinue CAR-T cell therapy development (lasme-cel and eti-cel) to prioritize in vivo gene editing therapies, citing limited cash resources. The announcement triggered a 40.97% stock price decline, prompting a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP on behalf of affected shareholders.

    CLLS
  2. The Law Offices Of Frank R. Cruz

    Securities Fraud Investigation Into Cellectis S.A. (CLLS) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

    The Law Offices of Frank R. Cruz is investigating Cellectis S.A. for potential securities law violations following the company's September 14, 2026 announcement to discontinue CAR-T cell therapies (lasme-cel and eti-cel) and prioritize in vivo gene editing therapies due to limited cash resources. The announcement triggered a 40.97% stock price decline, causing investor losses.

    CLLS